Narrow Results

Aloe vera ethanol extract (AVE) reportedly has significant anti-influenza virus activity, but its underlying mechanisms of action and constituents have not yet been completely elucidated. Previously, we have confirmed that AVE treatment significantly reduces the viral replication of green fluorescent protein-labeled influenza A virus in Madin-Darby canine kidney (MDCK) cells. In addition, post-treatment with AVE inhibited viral matrix protein 1 (M1), matrix protein 2 (M2), and hemagglutinin (HA) mRNA synthesis and viral protein (M1, M2, and HA) expressions. In this study, we demonstrated that AVE inhibited autophagy induced by influenza A virus in MDCK cells and also identified quercetin, catechin hydrate, and kaempferol as the active antiviral components of AVE. We also found that post-treatment with quercetin, catechin hydrate, and kaempferol markedly inhibited M2 viral mRNA synthesis and M2 protein expression. A docking simulation suggested that the binding affinity of quercetin, catechin hydrate, and kaempferol for the M2 protein may be higher than that of known M2 protein inhibitors. Thus, the inhibition of autophagy induced by influenza virus may explain the antiviral activity of AVE against H1N1 or H3N2. Aloe vera extract and its constituents may, therefore, be potentially useful for the development of anti-influenza agents.

WHO Update on Avian Influenza A (H5N1) — 14 January 2004.

WHO Update on Influenza A (H3N2) — 13 January 2004.

Endo wins suit to sell generic drug.

SINGAPORE – Intelligent Sensor Informs You to Change a Diaper via SMS

JAPAN – Tokyo Institute of Technology research: Key genetic event underlying fin-to-limb evolution

ISRAEL – Independent Results Show that BiondVax's Universal Flu Vaccine Administered in a Trial 3 Years ago Improves Immunogenicity against Current Flu H3N2 Epidemic

UNITED KINGDOM – Imperial Innovations Launches Orthonika: A Novel Knee Meniscus Replacement

UNITED KINGDOM – New Vaccine For Chlamydia to Use Synthetic Biology

CANADA – Aeterna Zentaris Announces Data and Safety Monitoring Board Scheduled to Complete Second Interim Analysis of the ZoptEC Phase 3 Trial in Endometrial Cancer in Early October

UNITED STATES – NueMD Launches Free ICD-10 Training Tool Ahead of October 1 Deadline

UNITED STATES – A new hope for Moderate and Severe Dementia: Upsher-Smith receives FDA approval for generic version of Namenda (Memantine HCL) Tablets

UNITED STATES – FDA Approves U.S. Product Labeling Update for Sprycel^® (dasatinib) to Include Five-Year First-Line and Seven-Year Second-Line Efficacy and Safety Data in Chronic Myeloid Leukemia in Chronic Phase